

AMERICAN VIETNAMESE  
BIOTECH INC

SOCIALIST REPUBLIC OF VIETNAM  
Independence - Freedom - Happiness

No: 27./2026/AMV

Regarding information disclosure and explanations  
Profit difference in the financial statements  
The year 2025 has been audited.

Ho Chi Minh City, May 15, 2026

**Dear:** - STATE SECURITIES COMMISSION;  
- HANOI STOCK EXCHANGE

Company Name: AMERICAN VIETNAMESE BIOTECH INC

Stock ticker: AMV

Head office address: 4th floor, Phu Ma Duong building, 85 Hoang Van Thai Street, Tan My Ward,  
Ho Chi Minh City

Phone: Fax:

Information released by: **Dang Nhi Nuong**

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai Street, Tan My Ward, Ho Chi  
Minh City

Telephone (mobile, office, home):

Type of information to be released: ☐ 24-hour ☐ irregular ☐ information as requested ☒  
periodically

Content of published information (\*):

In accordance with Circular No. 96/2020/TT-BTC dated November 16, 2020, of the Ministry of Finance, Viet My Pharmaceutical and Medical Equipment Manufacturing and Trading Joint Stock Company hereby reports to the Committee and the Department on the disclosure of the audited financial statements for the fiscal year ending December 31, 2025, as follows:

**I. Separate financial statements:**

**1. Explanation of changes in pre-tax profit in the Income Statement for the reporting period compared to the same period of the previous year:**

| Target                             | 2025 (VND)       | 2024 (VND)       | Difference (VND)  | Proportion |
|------------------------------------|------------------|------------------|-------------------|------------|
| Revenue from sales and services    | 26,092,083,075   | 169,364,910,851  | (143,272,827,776) | -84.59%    |
| Cost of goods sold                 | 23,253,299,467   | 160,394,730,660  | (137,141,431,193) | -85.50%    |
| Financial operating revenue        | 17.010.120.993   | 10,000,513,202   | 7,009,607,791     | 70.09%     |
| Total accounting profit before tax | (42,910,980,816) | (12,651,723,096) | (30,259,257,720)  | -239.17%   |

Profit before tax on the Company's audited 2025 Separate Financial Statements compared to the same period last year decreased by 239.17%, equivalent to the amount of VND 30,259,257,720. The main reason for the above fluctuations is that sales and service revenue in 2025 will only reach VND 26,092,083,075, down VND 143,272,827,776, equivalent to a decrease of 84.59% compared to 2024. The sharp decline in revenue stemmed from the Company's change in business strategy, whereby some items that were promoted

in 2024 were no longer focused on development in the fiscal year 2025. In addition, the cost of goods sold in 2025 will be 23,253,299,467 VND, down 137,141,431,193 VND, equivalent to a decrease of 85.50% compared to the previous year, in line with the decrease in revenue. However, the decrease in cost was not enough to offset the sharp decline in revenue, leading to less positive business results over the same period. In addition, revenue from financial activities in 2025 will reach VND 17,010,120,993, an increase of VND 7,009,607,791, equivalent to an increase of 70.09% compared to 2024. However, this increase is not enough to compensate for the large decrease from the main business, so pre-tax profit in 2025 will still decrease sharply compared to 2024.

## 2. Explanation of the difference in pre- and post-audit profit

+ Profit before tax before audit: (24,475,611,371) VND + Profit before tax according to the audited financial statements: (42,910,980,816) VND + Profit before tax according to the audited financial statements decreased: VND 18,435,369,445 (difference of 75.32%). The main reason for the above difference is that the Company makes additional provision for investment expenses, which increases costs in the period and leads to a decrease in pre-tax profit after the audit compared to the pre-audit figures

## II. Consolidated financial statements

### 1. Explanation of changes in pre-tax profit in the Income Statement for the reporting period compared to the same period of the previous year:

| Target                             | 2025 (VND)       | 2024 (VND)       | Difference (VND)  | Proportion |
|------------------------------------|------------------|------------------|-------------------|------------|
| Revenue from sales and services    | 159,996,502,630  | 310,354,603,848  | (150,358,101,218) | -48.45%    |
| Cost of goods sold                 | 137,822,998,853  | 279,093,183,419  | (141,270,184,566) | -50.62%    |
| Financial operating revenue        | 3,001,841,868    | 1,899,672,917    | 1,102,168,951     | 58.02%     |
| Total accounting profit before tax | (73,701,068,332) | (11,490,601,481) | (62,210,466,851)  | -541.40%   |

Profit before tax on the Company's audited 2025 Consolidated Financial Statements compared to the same period last year decreased by 541.40%. The main reason for the sharp decline in revenue comes from the Company's change in business strategy, whereby some items that were promoted in 2024 will no longer be focused on development in the fiscal year 2025. In addition, although revenue from financial activities increased by 58.02%, this increase was not enough to offset the decline in business revenue and the increase in expenses in the period, leading to a sharp decline in business results in 2025 compared to the same period last year.

## 2. Explanation of the difference in pre- and post-audit profit

+ Profit after tax before audit: (54,503,718,617) VND

+ Profit after tax according to the audited financial statements: (73,701,068,332) VND

+ Profit after tax according to the audited financial statements decreased: VND 19,197,349,715 (difference of 35.22%).

The main reason is that the Company makes additional provision for investment, which increases costs in the period, increases business management costs, leading to a decrease in pre-tax profit after the audit compared to the pre-audit figures.

III. The above information was posted on our company's website on May 15, 2025 at the following address:

<https://amvibiotech.com/category/bao-cao-tai-chinh/>

American Vietnamese Biotech Inc commits that the information provided above is truthful and accurate.

*Thank you very much!*

Recipient:

- As above.
- Save VP.

AMERICAN VIETNAMESE BIOTECH INC

MANAGER



**DANG NHI NUONG**

C.T.C.P.